Conclusions from study of entinostat combination to be tested in kidney, prostate cancer clinical trials
Thursday, February 23, 2012
BUFFALO, NY — Preclinical research by a team from Roswell Park Cancer Institute (RPCI) has demonstrated for the first time the way in which a class I histone deacetylase (HDAC) inhibitor, entinostat, appears to boost the effectiveness of cancer immunotherapy for treatment of some solid tumors...
Read more
Annual Becker’s Hospital Review feature highlights leaders in research, prevention, treatment and education
Wednesday, February 22, 2012
BUFFALO, NY — Roswell Park Cancer Institute (RPCI) has once again been included on Becker’s Hospital Review’s annual list of centers that serve as leaders in cancer research, prevention, treatment and education. In selecting facilities for its “Great Oncology Programs...
Read more
Staff to share information, assist with risk assessments at Feb. 26 event in Hamburg
Friday, February 17, 2012
BUFFALO, NY — Roswell Park Cancer Institute (RPCI) invites the community to the 2012 Western New York Health Expo Sunday, Feb. 26, at the Fairgrounds Event Center, Hamburg, NY, from 10am to 3pm. RPCI staff will share information on cancer prevention, risk factors, early detection, treatment...
Read more
Findings of International Tobacco Control study published in BMC Public Health
Wednesday, February 15, 2012
BUFFALO, NY — Smokers strongly favor decreasing the addictiveness of cigarettes, according to results from an International Tobacco Control (ITC) United States Supplemental Survey published in a recent issue of the journal BMC Public Health. The survey was conducted by a group of...
Read more
Friday, February 10, 2012
BUFFALO, NY — Several Roswell Park Cancer Institute (RPCI) faculty members have been selected to receive prestigious honors from their colleagues in recognition of their professional achievements, or have been elected to leadership positions in professional associations:
Read more
